IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
At a glance
- Drugs IO 101 (Primary) ; Imiquimod; Montanide ISA-51
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 12 Oct 2017 Five-year follow-up data were presented last month at the ESMO Congress 2017, as reported in an IO Biotech media release.
- 12 Oct 2017 Results published in an IO Biotech Media Release
- 12 Oct 2017 Results from this trial were published in Clinical Cancer Research, as reported in an IO Biotech media release.